Secukinumab, Pituitary Enlargement and Panhypopituitarism: Are They Related?

Pituitary adenomas are the most common cause of hypopituitarism associated with pituitary enlargement, but other aetiologies have been emerging, namely immune checkpoint inhibitor-induced hypophysitis (ipilimumab, nivolumab and pembrolizumab). Secukinumab is a recently approved human monoclonal anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramalho, Diogo, Araújo, André, Rocha, Gustavo, Duarte-Ribeiro, Filipa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SMC Media Srl 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8765694/
https://www.ncbi.nlm.nih.gov/pubmed/35059351
http://dx.doi.org/10.12890/2021_003099

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8765694/
https://www.ncbi.nlm.nih.gov/pubmed/35059351
http://dx.doi.org/10.12890/2021_003099

Ejemplares similares